Clinical trials located in

Nitra

Nitra city is located in Slovakia. Currently, 13 clinical trials are being conducted in this city.

Nitra, nestled in western Slovakia, is one of the country’s oldest cities, with roots stretching back to the 9th century. It’s renowned for its rich history, including the Nitra Castle, which dominates the city skyline, and the ancient Diocese of Nitra, one of the oldest in Slovakia. The city is also a vibrant agricultural hub, often referred to as the “Garden of Slovakia” due to its fertile lands and significant agricultural exhibition, Agrokomplex. Nitra’s blend of historical depth and cultural vitality makes it a unique Slovakian gem.

  • CT-EU-00057543

    Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    BelgiumBulgariaDenmarkItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Extended study on enzalutamide’s long-term effects in prostate cancer

    This is a follow-up study for people with prostate cancer that were involved in a previous trial with a drug named enzalutamide. The primary purpose of this study is to obtain long-term safety data of the drug. Participants will continue with the treatment plan they were on in the initial study if it benefits them. Doctor approval is necessary for any changes in treatment dosage. The study entails regular hospital visits every six months, give or take a week. At these visits, doctors will document any adverse effects, additional medications taken, and evaluate if continuation with the treatment is suitable.

    BelgiumFinlandFranceGermanyItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Long-term study on ofatumumab effects in relapsing multiple sclerosis atients

    This study is being conducted to assess the safety of long-term usage of a drug called ofatumumab in patients with relapsing multiple sclerosis, a condition that can disrupt the nervous system. As part of the study, an investigation is being carried out to determine the ease of administration and the efficacy of the drug. Individuals who have previously participated in other studies involving ofatumumab for multiple sclerosis are eligible to enroll in this study. A sub-study is also being conducted to examine the impact of ofatumumab on the body’s response to specific vaccines and an antigen known as KLH. Antigens are substances capable of triggering the production of antibodies in the body. Progress will be assessed based on the annual frequency of disease relapses and changes in disability, using the EDSS scale. EDSS evaluates factors such as vision, brain function, and walking ability.

    BulgariaCzechiaFranceGreeceHungaryPolandPortugalSlovakiaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    AustriaBelgiumCzechiaDenmarkFinlandGermanyHungaryItalyPolandPortugalSlovakiaSpainSweden
  • Mirikizumab’s role in treating active ulcerative colitis

    The study investigates the impact of mirikizumab in adults with moderately to severely active ulcerative colitis. Spanning 36 weeks, the trial evaluates the drug’s effectiveness in controlling symptoms and improving patients’ quality of life.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandSlovakiaUnited Kingdom
  • Examining the effectiveness of a new medicine for recent heart attack patients

    This trial is focused on a medicine called BI 765845, and it aims to determine its effectiveness for individuals who have experienced a heart attack. The objective is to assess the effectiveness of different quantities of the medicine when administered to these patients. Participation is limited to adults who have recently suffered a heart attack. During the study, some participants will receive the medicine, while others will be administered a placebo. The placebo lacks any medicinal properties. The likelihood of receiving the real medicine is four times greater than receiving the placebo. Over the next three months, participants will be requested to make multiple visits to the study site for heart health assessments. Any side effects will be documented and regularly monitored. The goal is to compare the results between the medicine and the placebo to determine which one is more effective.

    GermanyPolandSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Slovakia:

.